Leflunomide: An immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases

Immunopharmacology

Volumn 47, Issue 2-3, 2000, Pages 273-289

  Herrmann, Matthias L ^a   Schleyerbach, Rudolf ^a   Kirschbaum, Bernhard J ^a  

^a Hoechst Marion Roussel Deutschland GmbH   (United Kingdom)

Author keywords

DHODH, dihydroorotate dehydrogenase; Immunomodulation; Leflunomide; RA, rheumatoid arthritis; Rheumatoid arthritis; UMP, ribonucleotide uridine monophosphate

Indexed keywords

DIHYDROOROTATE DEHYDROGENASE; LEFLUNOMIDE; TERIFLUNOMIDE; URIDINE PHOSPHATE;

ANIMAL MODEL; AUTOIMMUNE DISEASE; B LYMPHOCYTE; DRUG MECHANISM; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; T LYMPHOCYTE;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISOXAZOLES; OXIDOREDUCTASES; OXIDOREDUCTASES ACTING ON CH-CH GROUP DONORS; PYRIMIDINES; T-LYMPHOCYTES;

EID: 0034122123     PISSN: 01623109     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0162-3109(00)00191-0     Document Type: Review

References (145)

1. Agarwal M.L., Agarwal A., Taylor W.R., Chernova O., Sharma Y., Stark G.R. A p53-dependent S-phase checkpoint helps to protect cells from DNA damage in response to starvation for pyrimidine nucleotides. Proc. Natl. Acad. Sci. U. S. A. 95(25):1998;14775-14780.
2. Allison A.C., Eugui E.M. Inhibitors of de novo purine and pyrimidine synthesis as immunosuppressive drugs. Transplant. Proc. 25(3 Suppl. 2):1993;8-18.
3. Allison A.C., Kowalski W.J., Muller C.J., Waters R.V., Eugui E.M. Mycophenolic acid and brequinar, inhibitors of purine and pyrimidine synthesis, block the glycosylation of adhesion molecules. Transplant. Proc. 25(3 Suppl 2):1993;67-70.
4. Antoniou E.A., Deroover A., Howie A.J., Chondros K., McMaster P., D'Silva M. Immunosuppressive effect of combination schedules of brequinar with leflunomide or tacrolimus on rat cardiac allotransplantation. Microsurgery. 19(2):1999;98-102.
5. Bartlett R.R., Schleyerbach R. Immunopharmacological profile of a novel isoxazol derivative, HWA 486, with potential antirheumatic activity: I. Disease modifying action on adjuvant arthritis of the rat. Int. J. Immunopharmacol. 7(1):1985;7-18.
6. Bartlett R.R. Immunopharmacological profile of HWA 486, a novel isoxazol derivative: II. In vivo immunomodulating effects differ from those of cyclophosphamide, prednisolone, or cyclosporin A. Int. J. Immunopharmacol. 8(2):1986;199-204.
7. Bartlett R.R., Popovic S., Raiss R.X. Development of autoimmunity in MRL/lpr mice and the effects of drugs on this murine disease. Scand. J. Rheumatol., Suppl. 75:1988;290-299.
8. Bartlett R.R., Anagnostopulos H., Zielinski T., Mattar T., Schleyerbach R. Effects of leflunomide on immune responses and models of inflammation. Springer Semin. Immunopathol. 14(4):1993;381-394.
9. Bartlett R.R., Brendel S., Zielinski T., Schorlemmer H.U. Leflunomide, an immunorestoring drug for the therapy of autoimmune disorders, especially rheumatoid arthritis. Transplant. Proc. 28(6):1996;3074-3078.
10. Berridge M.J., Irvine R.F. Inositol phosphates and cell signalling. Nature. 341(6239):1989;197-205.
11. Brazelton T.R., Morris R.E. Molecular mechanisms of action of new xenobiotic immunosuppressive drugs: tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide. Curr. Opin. Immunol. 8(5):1996;710-720.
12. Bruneau J.M., Yea C.M., Spinella-Jaegle S., Fudali C., Woodward K., Robson P.A., Sautes C., Westwood R., Kuo E.A., Williamson R.A., Ruuth E. Purification of human dihydro-orotate dehydrogenase and its inhibition by A77 1726, the active metabolite of leflunomide. Biochem. J. 336(Pt 2):1998;299-303.
13. Burmester G.R., Stuhlmuller B., Keyszer G., Kinne R.W. Mononuclear phagocytes and rheumatoid synovitis. Mastermind or workhorse in arthritis? Arthritis Rheum. 40(1):1997;5-18.
14. Calabrese L.H., Wilke W.S., Perkins A.D., Tubbs R.R. Rheumatoid arthritis complicated by infection with the human immunodeficiency virus and the development of Sjogren's syndrome. [see comments] Arthritis Rheum. 32(11):1989;1453-1457.
15. Cao W.W., Kao P.N., Chao A.C., Gardner P., Ng J., Morris R.E. Mechanism of the antiproliferative action of leflunomide. A77 1726, the active metabolite of leflunomide, does not block T-cell receptor-mediated signal transduction but its antiproliferative effects are antagonized by pyrimidine nucleosides. J. Heart Lung Transplant. 14(6 Pt 1):1995;1016-1030.
16. Cao W.W., Kao P.N., Aoki Y., Xu J.C., Shorthouse R.A., Morris R.E. A novel mechanism of action of the immunomodulatory drug, leflunomide: augmentation of the immunosuppressive cytokine, TGF-beta 1, and suppression of the immunostimulatory cytokine IL-2. Transplant. Proc. 28(6):1996;3079-3080.
17. Chernova O.B., Chernov M.V., Agarwal M.L., Taylor W.R., Stark G.R. The role of p53 in regulating genomic stability when DNA and RNA synthesis are inhibited. Trends Biochem. Sci. 20(10):1995;431-434.
18. Cherwinski H.M., McCarley D., Schatzman R., Devens B., Ransom J.T. The immunosuppressant leflunomide inhibits lymphocyte progression through cell cycle by a novel mechanism. J. Pharmacol. Exp. Ther. 272(1):1995;460-468.
19. Cherwinski H.M., Cohn R.G., Cheung P., Webster D.J., Xu Y.Z., Caulfield J.P., Young J.M., Nakano G., Ransom J.T. The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis. J. Pharmacol. Exp. Ther. 275(2):1995;1043-1049.
20. Chizzolini C., Chicheportiche R., Burger D., Dayer J.M. Human Th1 cells preferentially induce interleukin (IL)-1beta while Th2 cells induce IL-1 receptor antagonist production upon cell/cell contact with monocytes. Eur. J. Immunol. 27(1):1997;171-177.
21. Cohen A., Barankiewicz J., Lederman H.M., Gelfand E.W. Purine and pyrimidine metabolism in human T lymphocytes. Regulation of deoxyribonucleotide metabolism. J. Biol. Chem. 258(20):1983;12334-12340.
22. Constant S.L., Bottomly K. Induction of Th1 and Th2 CD4+T cell responses: the alternative approaches. Annu. Rev. Immunol. 15:1997;297-322.
23. Cush J.J., Lipsky P.E. Phenotypic analysis of synovial tissue and peripheral blood lymphocytes isolated from patients with rheumatoid arthritis. Arthritis Rheum. 31(10):1988;1230-1238.
24. Davis J.P., Cain G.A., Pitts W.J., Magolda R.L., Copeland R.A. The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase. Biochemistry. 35(4):1996;1270-1273.
25. Deage V., Burger D., Dayer J.M. Exposure of T lymphocytes to leflunomide but not to dexamethasone favors the production by monocytic cells of interleukin-1 receptor antagonist and the tissue-inhibitor of metalloproteinases-1 over that of interleukin-1beta and metalloproteinases. Eur. Cytokine Network. 9(4):1998;663-668.
26. Dimitrijevic M., Bartlett R.R. Leflunomide, a novel immunomodulating drug, inhibits homotypic adhesion of mononuclear cells in rheumatoid arthritis. Transplant. Proc. 28(6):1996;3086-3087.
27. Dudler J., So A.K. T cells and related cytokines. [see comments] Curr. Opin. Rheumatol. 10(3):1998;207-211.
28. Dunn EC., Small R. Leflunomide: an immunomodulatory agent for the treatment of rheumatoid arthritis. Formulary. 34:1999;21-31.
29. Eber E., Uhlig T., McMenamin C., Sly P.D. Leflunomide, a novel immunomodulating agent, prevents the development of allergic sensitization in an animal model of allergic asthma. Clin. Exp. Allergy. 28(3):1998;376-384.
30. Elder R.T., Xu X., Williams J.W., Gong H., Finnegan A., Chong A.S. The immunosuppressive metabolite of leflunomide, A77 1726, affects murine T cells through two biochemical mechanisms. J. Immunol. 159(1):1997;22-27.
31. Exton J.H. Signaling through phosphatidylcholine breakdown. J. Biol. Chem. 265(1):1990;1-4.
32. Fairbanks L.D., Bofill M., Ruckemann K., Simmonds H.A. Importance of ribonucleotide availability to proliferating T-lymphocytes from healthy humans. Disproportionate expansion of pyrimidine pools and contrasting effects of de novo synthesis inhibitors. J. Biol. Chem. 270(50):1995;29682-29689.
33. Fox R.I. Mechanism of action of leflunomide in rheumatoid arthritis. J. Rheumatol., Suppl. 53:1998;20-26.
34. Fox R.I., Mahboubi A., Green D., Sang B., Langford M., Frangou C.G., Herrmann M.L., Kirschbaum B.J. Leflunomide inhibits de novo uridine synthesis and is dependent on p53 for arrest in G1 phase of cell cycle. Arthritis Rheum. 41(Suppl 9):1998;S137.
35. Gero A.M., O'Sullivan W.J. Purines and pyrimidines in malarial parasites. Blood Cells. 16(2-3):1990;467-484.
36. Glant T.T., Mikecz K., Bartlett R.R., Deak F., Thonar E.J., Williams J.M., Mattar T., Kuettner K.E., Schleyerbach R. Immunomodulation of proteoglycan-induced progressive polyarthritis by leflunomide. Immunopharmacology. 23(2):1992;105-116.
37. Goronzy J.J., Weyand C.M. T and B cell-dependent pathways in rheumatoid arthritis. Curr. Opin. Rheumatol. 7(3):1995;214-221.
38. Graul A., Castaner J. Leflunomide. Drugs of the Future. 23(8):1998;827-837.
39. Greene S., Watanabe K., Braatz-Trulson J., Lou L. Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide. Biochem. Pharmacol. 50(6):1995;861-867.
40. Griffith D.A., Jarvis S.M. Nucleoside and nucleobase transport systems of mammalian cells. Biochim. Biophys. Acta. 1286(3):1996;153-181.
41. Gross W.L. New concepts in treatment protocols for severe systemic vasculitis. Curr. Opin. Rheumatol. 11(1):1999;41-46.
42. Hennet T., Chui D., Paulson J.C., Marth J.D. Immune regulation by the ST6Gal sialyltransferase. Proc. Natl. Acad. Sci. U. S. A. 95(8):1998;4504-4509.
43. Herrmann M.L., Frangou C.G., Kirschbaum B.J. Cell cycle control of the de novo pyrimidine synthesis inhibitor leflunomide through the p53 and p21WAF-1 pathway. Arthritis Rheum. 40(Suppl. 9):1997;S177.
44. Herrmann M.L., Frangou C.G., Simmonds H.A., Kirschbaum B.J. The primary mode of action of leflunomide in rheumatoid arthritis is inhibition of de novo pyrimidine synthesis. Arthritis Rheum. 41(Suppl. 9):1998;S35.
45. Hershfield M.S., Mitchell B.S. Scrivner C.R., Beaudet W.S., Sly W.S., Vall D. The Metabolic Basis of Inherited Disease. Vol. 7:1995;1725-1768 McGraw-Hill Book, New York.
46. Heubach G. Fungicidal isoxazol derivatives. Hoerlein G., Sachse B. Chem. Abstr. 86:1977;. 106569h.
47. Hoskin D.W., Taylor R.M., Makrigiannis A.P., James H., Lee T.D. Dose-dependent enhancing and inhibitory effects of A77 1726 (leflunomide) on cytotoxic T lymphocyte induction. Int. J. Immunopharmacol. 20(9):1998;505-513.
48. Hung D.T., Jamison T.F., Schreiber S.L. Understanding and controlling the cell cycle with natural products. Chem. Biol. 3(8):1996;623-639.
49. Hunter T. Protein kinases and phosphatases: the yin and yang of protein phosphorylation and signaling. Cell. 80(2):1995;225-236.
50. Jackowski S. Cell cycle regulation of membrane phospholipid metabolism. J. Biol. Chem. 271(34):1996;20219-20222.
51. Janossy G., Panayi G., Duke O., Bofill M., Poulter L.W., Goldstein G. Rheumatoid arthritis: a disease of T-lymphocyte/macrophage immunoregulation. Lancet. 2(8251):1981;839-842.
52. Jarman E.R., Kuba A., Montermann E., Bartlett R.R., Reske-Kunz A.B. Inhibition of murine IgE and immediate cutaneous hypersensitivity responses to ovalbumin by the immunomodulatory agent leflunomide. Clin. Exp. Immunol. 115(2):1999;221-228.
53. Jendro M.C., Ganten T., Matteson E.L., Weyand C.M., Goronzy J.J. Emergence of oligoclonal T cell populations following therapeutic T cell depletion in rheumatoid arthritis. Arthritis Rheum. 38(9):1995;1242-1251.
54. Jones M.E. Pyrimidine nucleotide biosynthesis in animals: genes, enzymes, and regulation of UMP biosynthesis. Annu. Rev. Biochem. 49:1980;253-279.
55. Karle J.M., Anderson L.W., Cysyk R.L. Effect of plasma concentrations of uridine on pyrimidine biosynthesis in cultured L1210 cells. J. Biol. Chem. 259(1):1984;67-72.
56. Katsafanas G.C., Grem J.L., Blough H.A., Moss B. Inhibition of vaccinia virus replication by N-(phosphonoacetyl)-L-aspartate: differential effects on viral gene expression result from a reduced pyrimidine nucleotide pool. Virology. 236(1):1997;177-187.
57. Kent C., Carman G.M., Spence M.W., Dowhan W. Regulation of eukaryotic phospholipid metabolism. FASEB J. 5(9):1991;2258-2266.
58. Kharbanda S.M., Sherman M.L., Kufe D.W. Effects of tiazofurin on guanine nucleotide binding regulatory proteins in HL-60 cells. Blood. 75(3):1990;583-588.
59. Kilshaw P.J., Brent L., Pinto M. Suppressor T cells in mice made unresponsive to skin allografts. Nature. 255(5508):1975;489-491.
60. Klimiuk P.A., Yang H., Goronzy J.J., Weyand C.M. Production of cytokines and metalloproteinases in rheumatoid synovitis is T cell dependent. Clin. Immunol. 90(1):1999;65-78.
61. Knecht W., Bergjohann U., Gonski S., Kirschbaum B., Loffler M. Functional expression of a fragment of human dihydroorotate dehydrogenase by means of the baculovirus expression vector system, and kinetic investigation of the purified recombinant enzyme. Eur. J. Biochem. 240(1):1996;292-301.
62. Knecht W., Loffler M. Species-related inhibition of human and rat dihydroorotate dehydrogenase by immunosuppressive isoxazol and cinchoninic acid derivatives. Biochem. Pharmacol. 56(9):1998;1259-1264.
63. Ko L.J., Prives C. p53: puzzle and paradigm. Genes Dev. 10(9):1996;1054-1072.
64. Korganow A.S., Ji H., Mangialaio S., Duchatelle V., Pelanda R., Martin T., Degott C., Kikutani H., Rajewsky K., Pasquali J.L., Benoist C., Mathis D. From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins. Immunity. 10(4):1999;451-461.
65. Kouskoff V., Korganow A.S., Duchatelle V., Degott C., Benoist C., Mathis D. Organ-specific disease provoked by systemic autoimmunity. Cell. 87(5):1996;811-822.
66. Kuo E.A., Hambleton P.T., Kay D.P., Evans P.L., Matharu S.S., Little E., McDowall N., Jones C.B., Hedgecock C.J., Yea C.M., Chan A.W., Hairsine P.W., Ager I.R., Tully W.R., Williamson R.A., Westwood R. Synthesis, structure-activity relationships, and pharmacokinetic properties of dihydroorotate dehydrogenase inhibitors: 2-cyano-3-cyclopropyl-3-hydroxy-N-[3′-methyl-4′-(trifluoromethyl) phenyl]propenamide and related compounds. J. Med. Chem. 39(23):1996;4608-4621.
67. Lacraz S., Isler P., Vey E., Welgus H.G., Dayer J.M. Direct contact between T lymphocytes and monocytes is a major pathway for induction of metalloproteinase expression. J. Biol. Chem. 269(35):1994;22027-22033.
68. Lang R., Wagner H., Heeg K. Differential effects of the immunosuppressive agents cyclosporine and leflunomide in vivo. Leflunomide blocks clonal T cell expansion yet allows production of lymphokines and manifestation of T cell-mediated shock. Transplantation. 59(3):1995;382-389.
69. Levine A.J. p53, the cellular gatekeeper for growth and division. Cell. 88(3):1997;323-331.
70. Levitzki A., Gazit A. Tyrosine kinase inhibition: an approach to drug development. Science. 267(5205):1995;1782-1788.
71. Lin Y., Sobis H., Vandeputte M., Waer M. Long-term xenograft survival and suppression of xenoantibody formation in the hamster-to-rat heart transplant model using a combination therapy of leflunomide and cyclosporine. Transplant. Proc. 26(6):1994;3202.
72. Lin Y., Waer M. In vivo mechanism of action of leflunomide: selective inhibition of the capacity of B lymphocytes to make T-independent xenoantibodies. Transplant. Proc. 28(6):1996;3085.
73. Lin Y., Vandeputte M., Waer M. Natural killer cell- and macrophage-mediated rejection of concordant xenografts in the absence of T and B cell responses. J. Immunol. 158(12):1997;5658-5667.
74. Lin Y., Vandeputte M., Waer M. Accommodation and T-independent B cell tolerance in rats with long term surviving hamster heart xenografts. J. Immunol. 160(1):1998;369-375.
75. Lin Y., Goebels J., Xia G., Ji P., Vandeputte M., Waer M. Induction of specific transplantation tolerance across xenogeneic barriers in the T-independent immune compartment. Nat. Med. 4(2):1998;173-180.
76. Linke S.P., Clarkin K.C., Di Leonardo A., Tsou A., Wahl G.M. A reversible, p53-dependent G0/G1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage. Genes Dev. 10(8):1996;934-947.
77. Lirtzman R.A., Gregory C.R., Levitski R.E., Griffey S.M., Yeh L.S., Patz J.D., Morris R.E. Combined immunosuppression with leflunomide and cyclosporine prevents MLR-mismatched renal allograft rejection in a mongrel canine model. Transplant. Proc. 28(2):1996;945-947.
78. Lombardi G., Sidhu S., Batchelor R., Lechler R. Anergic T cells as suppressor cells in vitro. [see comments] Science. 264(5165):1994;1587-1589.
79. Lucien J., Dias V.C., LeGatt D.F., Yatscoff R.W. Blood distribution and single-dose pharmacokinetics of leflunomide. Ther. Drug Monit. 17(5):1995;454-459.
80. Lucien J., Marath A., Rayat G., Thliveris J., Koshal A., Yatscoff R. Efficacy of leflunomide to reduce xenoantibody titers in vivo: an evaluation of the prolongation of discordant xenograft survival. Transplant. Proc. 28(2):1996;704-707.
81. Mahajan S., Ghosh S., Sudbeck E.A., Zheng Y., Downs S., Hupke M., Uckun F.M. Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK) LFM-A13 [alpha-cyano-beta-hydroxy-beta-methyl-N-(2, 5-dibromophenyl)propenamide]. J. Biol. Chem. 274(14):1999;9587-9599.
82. Manna S.K., Aggarwal B.B. Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression. J. Immunol. 162(4):1999;2095-2102.
83. Marijnen Y.M., de Korte D., Haverkort W.A., den Breejen E.J., van Gennip A.H., Roos D. Studies on the incorporation of precursors into purine and pyrimidine nucleotides via 'de novo' and 'salvage' pathways in normal lymphocytes and lymphoblastic cell-line cells. Biochim. Biophys. Acta. 1012(2):1989;148-155.
84. Mattar T., Kochhar K., Bartlett R., Bremer E.G., Finnegan A. Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide. FEBS Lett. 334(2):1993;161-164.
85. Matteson E.L. Recent clinical trials in the rheumatic diseases. [see comments] Curr. Opin. Rheumatol. 9(2):1997;95-101.
86. Mendz G.L., Jimenez B.M., Hazell S.L., Gero A.M., O'Sullivan W.J. De novo synthesis of pyrimidine nucleotides by Helicobacter pylori. J. Appl. Bacteriol. 77(1):1994;1-8.
87. Metzler C., Löw-Friedrich I., Reinhold-Kessler E., Schmitt W.H., Gross W.L. Leflunomide, a new promising agent in maintenance of remission in Wegener's granulomatosis. Clin. Exp. Immunol. 112:1998;56.
88. Milbert U., Schorlemmer H.U., Haun G., Wunschel M., Fudali C.R.E., Bartlett R.R. Chromatographic separation with subsequent detection of changes in conductivity as a useful tool to detect an increase in the L-dihydroorotic acid (L-DHO) content of cell lysates and serum. Int. J. Immunopharmacol. 14(4):1998;223-232.
89. Mladenovic V., Domljan Z., Rozman B., Jajic I., Mihajlovic D., Dordevic J., Popovic M., Dimitrijevic M., Zivkovic M., Campion G. Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Results of a randomized, placebo-controlled, phase II study. Arthritis Rheum. 38(11):1995;1595-1603.
90. Moots R.J. A fistful of T cells. Br. J. Rheumatol. 37(6):1998;602-611.
91. Morford G., Davidson J.N., Snow E.C. Appearance of CAD activity, the rate-limiting enzyme for pyrimidine biosynthesis, as B cells progress into and through the G1 stage of the cell cycle. Cell. Immunol. 158(1):1994;96-104.
92. Muller-Ladner U. Molecular and cellular interactions in rheumatoid synovium. Curr. Opin. Rheumatol. 8(3):1996;210-220.
93. Nair R.V., Cao W., Morris R.E. Inhibition of smooth muscle cell proliferation in vitro by leflunomide, a new immunosuppressant, is antagonized by uridine. Immunol. Lett. 48(2):1995;77-80.
94. O'Dwyer P.J. The role of low-dose PALA in biochemical modulation. Pharmacol. Ther. 48(3):1990;371-380.
95. Ogawa T., Inazu M., Gotoh K., Hayashi S. Effects of leflunomide on glomerulonephritis induced by antibasement membrane antibody in rats. Agents Actions. 31(3-4):1990;321-328.
96. Osherov N., Gazit A., Gilon C., Levitzki A. Selective inhibition of the epidermal growth factor and HER2/neu receptors by tyrphostins. J. Biol. Chem. 268(15):1993;11134-11142.
97. Panayi G.S. T-cell-dependent pathways in rheumatoid arthritis. Curr. Opin. Rheumatol. 9(3):1997;236-240.
98. Papageorgiou C., Albert R., Floersheim P., Lemaire M., Bitch F., Weber H.P., Andersen E., Hungerford V., Schreier M.H. Pyrazole bioisosteres of leflunomide as B-cell immunosuppressants for xenotransplantation and chronic rejection: scope and limitations. J. Med. Chem. 41(18):1998;3530-3538.
99. Paul W.E., Seder R.A. Lymphocyte responses and cytokines. Cell. 76(2):1994;241-251.
100. Paulson J.C. Glycoproteins: what are the sugar chains for? Trends Biochem Sci. 14(7):1989;272-276.
101. Peters G.J., Pinedo H.M., Ferwerda W., de Graaf T.W., van Dijk W. Do antimetabolites interfere with the glycosylation of cellular glycoconjugates? Eur. J. Cancer. 26(4):1990;516-523.
102. Peters G.J., Schwartsmann G., Nadal J.C., Laurensse E.J., van Groeningen C.J., van der Vijg W.J., Pinedo H.M. In vivo inhibition of the pyrimidine de novo enzyme dihydroorotic acid dehydrogenase by brequinar sodium (DUP-785; NSC 368390) in mice and patients. Cancer Res. 50(15):1990;4644-4649.
103. Popovic S., Bartlett R.R. Disease modifying activity of HWA 486 on the development of SLE in MRL/1-mice. Agents Actions. 19(5-6):1986;313-314.
104. Popovic S., Bartlett R.R. The use of the murine chronic graft vs host (CGVH) disease, a model for systemic lupus erythematosus (SLE), for drug discovery. Agents Actions. 21(3-4):1987;284-286.
105. Qin S., Cobbold S.P., Pope H., Elliott J., Kioussis D., Davies J., Waldmann H. "Infectious" transplantation tolerance. Science. 259(5097):1993;974-977.
106. Richard M., Hoskin D.W. Inhibition of anti-CD3 antibody-induced mouse T cell activation by pentoxifylline in combination with rapamycin or A77 1726 (leflunomide). Int. J. Immunopharmacol. 20(4-5):1998;241-252.
107. Rittner H.L., Zettl A., Jendro M.C., Bartz-Bazzanella P., Goronzy J.J., Weyand C.M. Multiple mechanisms support oligoclonal T cell expansion in rheumatoid synovitis. Mol. Med. 3(7):1997;452-465.
108. Robertson S.M., Lang L.S. Leflunomide: inhibition of S-antigen induced autoimmune uveitis in Lewis rats. Agents Actions. 42(3-4):1994;167-172.
109. Ruckemann K., Fairbanks L.D., Carrey E.A., Hawrylowicz C.M., Richards D.F., Kirschbaum B., Simmonds H.A. Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans. J. Biol. Chem. 273(34):1998;21682-21691.
110. Ruderman E.M., Weinblatt M.E., Thurmond L.M., Pinkus G.S., Gravallese E.M. Synovial tissue response to treatment with Campath-1H. [see comments] Arthritis Rheum. 38(2):1995;254-258.
111. Schorlemmer H.U., Seiler F.R., Bartlett R.R. Prolongation of allogeneic transplanted skin grafts and induction of tolerance by leflunomide, a new immunosuppressive isoxazol derivative. Transplant. Proc. 25(1 Pt 1):1993;763-767.
112. Sgroi D., Nocks A., Stamenkovic I. A single N-linked glycosylation site is implicated in the regulation of ligand recognition by the I-type lectins CD22 and CD33. J. Biol. Chem. 271(31):1996;18803-18809.
113. Siemasko K.F., Chong A.S., Williams J.W., Bremer E.G., Finnegan A. Regulation of B cell function by the immunosuppressive agent leflunomide. Transplantation. 61(4):1996;635-642.
114. Siemasko K., Chong A.S., Jack H.M., Gong H., Williams J.W., Finnegan A. Inhibition of JAK3 and STAT6 tyrosine phosphorylation by the immunosuppressive drug leflunomide leads to a block in IgG1 production. J. Immunol. 160(4):1998;1581-1588.
115. Silva H.T., Shorthouse R., Morris R.E. Single- and multiple-dose pharmacokinetics and pharmacodynamics of leflunomide's active metabolite A77 1726 in normal Lewis rats. Transplant. Proc. 28(6):1996;3092-3094.
116. Silva H.T., Cao W., Shorthouse R., Morris R.E. Mechanism of action of leflunomide: in vivo uridine administration reverses its inhibition of lymphocyte proliferation. Transplant. Proc. 28(6):1996;3082-3084.
117. Silva J.H., Morris R.E. Leflunomide and malononitrilamides. Am. J. Med. Sci. 313(5):1997;289-301.
118. Silva H.T.J., Cao W., Shorthouse R.A., Loffler M., Morris R.E. In vitro and in vivo effects of leflunomide, brequinar, and cyclosporine on pyrimidine biosynthesis. Transplant. Proc. 29(1-2):1997;1292-1293.
119. Simmonds H.A. Enzymes of nucleotide biosynthesis: differences between intact and lysed cells as well as between species and tissues can be important. Biochem. Soc. Trans. 23(4):1995;877-879.
120. Simmonds H.A., Panayi G.S., Corrigall V. A role for purine metabolism in the immune response: adenosine-deaminase activity and deoxyadenosine catabolism. Lancet. 1(8055):1978;60-63.
121. Slauson S.D., Silva H.T., Sherwood S.W., Morris R.E. Flow cytometric analysis of the molecular mechanisms of immunosuppressive action of the active metabolite of leflunomide and its malononitrilamide analogues in a novel whole blood assay. [In Process Citation] Immunol. Lett. 67(3):1999;179-183.
122. Sloan-Lancaster J., Allen P.M. Altered peptide ligand-induced partial T cell activation: molecular mechanisms and role in T cell biology. Annu. Rev. Immunol. 14:1996;1-27.
123. Smith-Lang L., Glaser R.L., Miller S.T., Weimer L.K., Robertson S.M., Aoki K.R. Efficacy of novel immunomodulators leflunomide and rapamycin in autoimmune uveitis. FASEB J. 6(4):1999;A1048.
124. Smolen J.S., Kalden J.R., Scott D.L., Rozman B., Kvien T.K., Larsen A., Loew-Friedrich I., Oed C., Rosenburg R. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. [see comments] Lancet. 353(9149):1999;259-266.
125. Steinman L. A few autoreactive cells in an autoimmune infiltrate control a vast population of nonspecific cells: a tale of smart bombs and the infantry. Proc. Natl. Acad. Sci. U. S. A. 93:1996;2253-2256.
126. Stosic-Grujicic S., Dimitrijevic M., Bartlett R. Leflunomide protects mice from multiple low dose streptozotocin (MLD-SZ)-induced insulitis and diabetes. Clin. Exp. Immunol. 117(1):1999;44-50.
127. Strand V., Tugwell P., Bombardier C., Maetzel A., Crawford B., Dorrier C., Thompson A., Wells G. Function and health-related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. [In Process Citation] Arthritis Rheum. 42(9):1999;1870-1878.
128. +T cell clones in the synovial fluid of patients with rheumatoid arthritis. J. Immunol. 161(8):1998;4428-4436.
129. Terce F., Brun H., Vance D.E. Requirement of phosphatidylcholine for normal progression through the cell cycle in C3H/10T1/2 fibroblasts. J. Lipid Res. 35(12):1994;2130-2142.
130. Vance D.E. Boehringer Mannheim Award lecture. Phosphatidylcholine metabolism: masochistic enzymology, metabolic regulation, and lipoprotein assembly. Biochem. Cell Biol. 68(10):1990;1151-1165.
131. Vidic-Dankovic B., Kosec D., Damjanovic M., Apostolski S., Isakovic K., Bartlett R.R. Leflunomide prevents the development of experimentally induced myasthenia gravis. Int. J. Immunopharmacol. 17(4):1995;273-281.
132. Wagner U.G., Koetz K., Weyand C.M., Goronzy J.J. Perturbation of the T cell repertoire in rheumatoid arthritis. Proc. Natl. Acad. Sci. U. S. A. 95(24):1998;14447-14452.
133. Waldman W.J., Knight D.A., Lurain N.S., Miller D.M., Sedmak D.D., Williams J.W., Chong A.S. Novel mechanism of inhibition of cytomegalovirus by the experimental immunosuppressive agent leflunomide. [In Process Citation] Transplantation. 68(6):1999;814-825.
134. Weber W., Harnisch L. Use of a population pharmacokinetic model to predict clinical outcome of leflunomide, a new DMARD in the treatment of rheumatoid arthritis. Aaronson L., Balant L.P., Danhof M. European cooperation in the field of scientific and technical research. 1997;239-244 European Commision Directorate General Science, Research and Development, Brussels.
135. Webster D.R., Becroft D.M.O., Suttle D.P. Scriver C.R., Beaude A.L., Sly W.S., Valle D. Hereditary Orotic Aciduria and Other Disorders of Pyrimidine Metabolism. Vol. (43):1995;1095-1126 McGraw-Hill Book, New York.
136. Weinblatt M.E., Kremer J.M., Coblyn J.S., Maier A.L., Helfgott S.M., Morrell M., Byrne V.M., Kaymakcian M.V., Strand V. Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. [In Process Citation] Arthritis Rheum. 42(7):1999;1322-1328.
137. Wierda D., Pazdernik T.L. Uridine transport in concanavalin A- and lipopolysaccharide-activated mouse lymphocytes. Biochem. Pharmacol. 30(24):1981;3295-3303.
138. Williams J.W., Xiao F., Foster P., Clardy C., McChesney L., Sankary H., Chong A.S. Leflunomide in experimental transplantation. Control of rejection and alloantibody production, reversal of acute rejection, and interaction with cyclosporine. Transplantation. 57(8):1994;1223-1231.
139. Williamson R.A., Yea C.M., Robson P.A., Curnock A.P., Gadher S., Hambleton A.B., Woodward K., Bruneau J.M., Hambleton P., Moss D. Dihydroorotate dehydrogenase is a high affinity binding protein for A77 1726 and mediator of a range of biological effects of the immunomodulatory compound. J. Biol. Chem. 270(38):1995;22467-22472.
140. Williamson R.A., Yea C.M., Robson P.A., Curnock A.P., Gadher S., Hambleton A.B., Woodward K., Bruneau J.M., Hambleton P., Spinella-Jaegle S., Morand P., Courtin O., Sautes C., Westwood R., Hercend T., Kuo E.A., Ruuth E. Dihydroorotate dehydrogenase is a target for the biological effects of leflunomide. Transplant. Proc. 28(6):1996;3088-3091.
141. Xu X., Williams J.W., Bremer E.G., Finnegan A., Chong A.S. Inhibition of protein tyrosine phosphorylation in T cells by a novel immunosuppressive agent, leflunomide. J. Biol. Chem. 270(21):1995;12398-12403.
142. Xu X., Williams J.W., Gong H., Finnegan A., Chong A.S. Two activities of the immunosuppressive metabolite of leflunomide, A77 1726. Inhibition of pyrimidine nucleotide synthesis and protein tyrosine phosphorylation. Biochem. Pharmacol. 52(4):1996;527-534.
143. Xu X., Blinder L., Shen J., Gong H., Finnegan A., Williams J.W., Chong A.S. In vivo mechanism by which leflunomide controls lymphoproliferative and autoimmune disease in MRL/MpJ-lpr/lpr mice. J. Immunol. 159(1):1997;167-174.
144. Yednock T.A., Rosen S.D. Lymphocyte homing. Adv. Immunol. 44:1989;313-378.
145. Zielinski T., Herrmann M.L., Riedel N., Bartlett R.R. The influence of leflunomide on cell cycle, IL-2-receptor (IL-2-R) and its gene expression. Agents Actions. 41:1994;C204-C205.